- PR Newswire•8 days agoZIOPHARM and Intrexon Announce Cooperative Research and Development Agreement with the National Cancer Institute Utilizing Sleeping Beauty System to Generate T cells Targeting Neoantigens
BOSTON and GERMANTOWN, Md., Jan. 10, 2017 /PRNewswire/ -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, and Intrexon Corporation (NYSE:XON), a leader ...
- Benzinga•9 days agoExclusive: Ziopharm CEO Talks Partnerships, Balance Sheet And JPM Healthcare Conference Presentation
Benzinga recently had the chance to speak with ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) CEO Dr. Laurence James Neil Cooper about the upcoming JPMorgan Healthcare Conference, partnerships with Intrexon Corp ...
- GlobeNewswire•14 days ago
BOSTON, Jan. 04, 2017-- ZIOPHARM Oncology, Inc. today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 35 th Annual J.P. Morgan Healthcare Conference in San Francisco ...
ZIOP : Summary for ZIOPHARM Oncology Inc - Yahoo Finance
ZIOPHARM Oncology, Inc. (ZIOP)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||5.75 x 1000|
|Ask||5.86 x 1000|
|Day's Range||5.70 - 6.08|
|52 Week Range||4.45 - 9.74|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-4.51|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|